Polaryx Therapeutics, Inc. Statistics
Polaryx Therapeutics, Inc. (PLYX) Stock Statistics & Valuation Metrics
Total Valuation
Polaryx Therapeutics, Inc. has a market cap or net worth of $75.27M. The enterprise value is $106.28T.
- Market Cap
- $75.27M
- Enterprise Value
- $106.28T
Share Statistics
Polaryx Therapeutics, Inc. has 49,845,993 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 49,845,993
- Owned by Insiders
- 49.07%
- Owned by Institutions
- 6.27%
Financial Efficiency
Polaryx Therapeutics, Inc.’s return on equity (ROE) is -1.97 and return on invested capital (ROIC) is -171.33%.
- Return on Equity (ROE)
- -1.97
- Return on Assets (ROA)
- -1.74
- Return on Invested Capital (ROIC)
- -171.33%
- Return on Capital Employed (ROCE)
- -1.71
- Revenue Per Employee
- 0
- Profits Per Employee
- -816.82K
- Employee Count
- 11
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Polaryx Therapeutics, Inc. is -7.35. Polaryx Therapeutics, Inc.’s PEG ratio is 0.08.
- PE Ratio
- -7.35
- PS Ratio
- 0.00
- PB Ratio
- 8.71
- Price to FCF
- -8.26
- Price to Operating Cash Flow
- -8.26
- PEG Ratio
- 0.08
Income Statement
In the last 12 months, Polaryx Therapeutics, Inc. had revenue of 0 and earned -8.98M in profits. Earnings per share was -0.19.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -7.82M
- Pretax Income
- -8.98M
- Net Income
- -8.98M
- EBITDA
- -8.98M
- Earnings Per Share (EPS)
- -0.19
Cash Flow
In the last 12 months, operating cash flow was -8.02M and capital expenditures 0, giving a free cash flow of -8.02M billion.
- Operating Cash Flow
- -8.02M
- Free Cash Flow
- -8.02M
- Free Cash Flow per Share
- -0.16
Dividends & Yields
Polaryx Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.84%
- Earnings Yield
- -12.90%
Stock Price Statistics
- Beta
- 0.35
- 52-Week Price Change
- -96.20%
- 50-Day Moving Average
- 1.94
- 200-Day Moving Average
- 3.09
- Relative Strength Index (RSI)
- 25.52
- Average Volume (3m)
- 36.52K
Financial Position
Polaryx Therapeutics, Inc. as a current ratio of 8.55, with Debt / Equity ratio of 0.00%
- Current Ratio
- 8.55
- Quick Ratio
- 8.55
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.57
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Polaryx Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Polaryx Therapeutics, Inc. EV to EBITDA ratio is -6.79, with an EV/FCF ratio of -7.40.
- EV to Sales
- 0.00
- EV to EBITDA
- -6.79
- EV to Free Cash Flow
- -7.40
- EV to Operating Cash Flow
- -7.40
Balance Sheet
Polaryx Therapeutics, Inc. has $8.44M in cash and marketable securities with $0.00 in debt, giving a net cash position of $8.44M billion.
- Cash & Marketable Securities
- $8.44M
- Total Debt
- $0.00
- Net Cash
- $8.44M
- Net Cash Per Share
- $0.17
- Tangible Book Value Per Share
- $0.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Polaryx Therapeutics, Inc. is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $10.00
- Price Target Upside
- 651.88% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -4.21%
Scores
- Smart Score
- 3
- AI Score
- ―

